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Abstract
Background: WHO recommends intermittent-preventive-treatment (IPTp) with sulphadoxine-pyrimethamine (SP) and
insecticide-treated-nets (ITNs) to prevent malaria in pregnancy in sub-Saharan Africa, however uptake remains unacceptably
low. We evaluated the effectiveness of antenatal clinics (ANC) to deliver two doses of IPTp and ITNs to pregnant women in
Segou district, Mali.
Methods: We used household data to assess the systems effectiveness of ANC to deliver IPTp and ITNs to pregnant women
and used logistic regression to identify predictors of ANC attendance, receipt of IPTp and ITN use during pregnancy, and the
impact on community effectiveness.
Results: Of 81% of recently pregnant women who made at least one ANC visit, 59% of these attended during the eligible
gestational age for IPTp. Of these, 82% reported receiving one dose of SP and 91% attended ANC again, of whom 66%
received a second dose, resulting in a cumulative effectiveness for 2-dose IPTp of 29%, most of whom used an ITN (90%).
Cumulative effectiveness of 2-dose SP by directly observed therapy (DOT) was very low (6%). ITN use was 92%, and ANC was
the main source (81%). Reported and ANC-card data showed some doses of SP are given to women in their first trimester.
Women were less likely to receive two doses by DOT if they were married (OR 0.10; CI 0.03, 0.40), or lived ,5 km from the
health facility (OR 0.34; CI 0.14, 0.83). A high household person-LLIN ratio predicted low ITN use in pregnant women (OR
0.16; CI 0.04, 0.55).
Conclusion: Our findings suggest poor adherence by health workers to provision of IPTp by eligible gestational age and
DOT, contributing to low effectiveness of this strategy in this setting. ITN delivery and use among women was substantially
higher. Efforts to improve health worker adherence to IPTp guidelines are needed to improve service delivery of IPTp.
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Background
Since 2004, the World Health Organization (WHO) has
recommended a package of intermittent preventive treatment
(IPTp) and insecticide treated nets (ITNs) together with effective
management of clinical malaria and anaemia for malaria
prevention and control during pregnancy in areas of stable
malaria transmission in sub-Saharan Africa [1]. Until 2012, WHO
recommended two doses of sulphadoxine-pyrimethamine, (SP)
administered in the second and third trimesters of pregnancy [1].
These interventions can substantially reduce disease burden and
adverse outcomes of malaria in pregnancy [2–4], and are
inexpensive and cost effective [5]. Although these interventions
have been available for over two decades [2–4], access to and use
by pregnant women remains unacceptably low [6].
The Roll Back Malaria Partnership aims to ensure that by 2015,
all pregnant women living in areas of high-intensity transmission
in sub-Saharan Africa receive IPTp and use ITNs [7]. IPTp with
SP is delivered to pregnant women through antenatal clinics
(ANC) alongside ITNs. Despite almost universally high levels of
ANC coverage in sub-Saharan Africa, coverage estimates for IPTp
and ITNs in sub-Saharan Africa have increased only modestly
between 2007 and 2010, from 13.6% to 21?5% and from 17.0% to
38?8% for IPTp and ITNs respectively, representing substantial
missed opportunities at ANC [6]. According to the Countdown to
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2015 Decade Report, in 20 countries with data, IPTp and ITNs,
together with case management of malaria during pregnancy,
have the lowest coverage among all the interventions delivered to
pregnant women at ANC [8]. The reasons for this are diverse and
stem from barriers to delivery as well as user behaviours, as
described in a recent systematic review of the factors affecting the
delivery, access and use of IPTp and ITNs [9]. For example two
studies reported that health workers do not always offer IPTp to
women at ANC [10,11]. It is a particular concern that health
services have been unable to deliver IPTp-SP effectively, as this
relatively simple and cost effective regimen will most likely be
replaced with more complicated and expensive drug regimens or
Table 1. Socio-demographic characteristics of the respondents.
Socio-demographic data Pregnant women (N=150) Recently pregnant women (N=264)
Characteristic n % (95% CI) n % (95% CI)
Trimester
1st trimester 19 12.7
2nd trimester 62 41.3
3rd trimester 70 46.0
Median months gestational age 150 6 (IQR 4–8)
Gravidity
Gravida 1 16 10.7 47 18.4
Gravida 2 20 13.3 48 18.8
Gravida 3. 114 76.0 160 62.8
Median number of births 150 3 (IQR 2–6) 264 4 (IQR 2–6)
Age group (15–49 years)
15to19 23 15.3 46 17.4
20to24 27 18.0 61 23.1
25to29 47 31.3 64 24.2
30to34 34 22.7 56 21.2
35to39 11 7.3 24 9.1
40+ 8 5.3 13 4.9
Median Age 27 (IQR 22–30) 25 (IQR 21–30)
Marital status
Married 145 96.7 245 92.8
Divorced/separated 1 0.7 0 0.0
Single 4 2.7 19 7.2
Location of residence
Urban 45 30.0 6 32.6
Rural 105 70.0 178 67.4
Education level
None/nursery 100 66.7 164 62.1
Primary 46 30.7 83 31.4
Secondary/College/University 4 2.7 17 6.4
Ethnic Group
Bambara 87 58.0 146 55.3
Peulh 16 10.7 38 14.4
Malinke 4 2.7 8 3.0
Bozo/Somono 4 2.7 5 1.9
Dogon 1 0.7 4 1.5
Other 38 25.3 63 23.9
HIV status (self reported) 0/32 0 1/50 2.0 (0.3, 14.2)
Women with child aged ,1 year 5/134* 3.7 (1.6, 8.5) 264/264 100.0 (2)
Women with child aged ,5 years 110/134* 82.1(74.0,88.1) 264/264 100.0 (2)
Woman has lost a child 60/134* 44.8 (36.1,53.8) 99/264 37.5 (30.5,45.1)
N, denominator; n, numerator; CI, confidence interval; IQR, inter-quartile range; HIV, human immunodeficiency virus.
*excludes primigravid women.
doi:10.1371/journal.pone.0092102.t001
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new strategies [12] in the near future due to increasing resistance
to SP [3,13]. These alternative prevention strategies will present
even greater challenges for effective delivery or systems effective-
ness [14,15].
A recent systematic review identified very few studies that
evaluated the effectiveness of the delivery of IPTp [16] and ITNs
[17,18] through ANC. New methods are required to measure the
relative impact of the different barriers to the delivery of these
important interventions in order that programme managers can
achieve the best value for money by prioritising which barriers to
target in order to improve uptake. This study used household
survey data to measure the effectiveness of the delivery of IPTp-SP
and ITNs to pregnant women through ANC in one district in
Mali, and assessed the predictors of effective delivery.
Table 2. Key coverage indicators for ANC attendance and malaria in pregnancy interventions among pregnant and recently
pregnant women.
Coverage Indicators Pregnant women (N=150) Recently pregnant women (N=264)
n/N % (95% CI) n/N % (95% CI)
Number ANC visits
At least one visit 94/150 62.7 (52.8, 71.6) 215/264 81.4 (75.2,86.4)
At least two visits 64/150 42.7 (33.6, 52.2) 198/264 75.0 (68.2, 80.8)
4 or more visits 23/150 15.3 (9.7, 23.4) 112/264 42.4 (34.6, 50.6)
Median number of ANC visits among ANC attendees 94 2 (IQR 1–3) 215 4 (IQR 3–5)
Gestational age at 1st ANC visit
0–3 months 34/93 36.6 (25.6,49.1) 88/215 40.9 (33.0,49.3)
4–6 months 53/93 57.0 (45.8,67.5) 102/215 47.4 (40.4,54.6)
7–9 months 6/93 6.5 (2.7,14.5) 25/215 11.6 (7.2,18.2)
Median gestational age at 1st ANC visit 92 4 (IQR 3–5) 208 4 (IQR 3–5)
1 dose SP{
1 dose (all trimesters, any source) 199/264 75.1 (68.3, 80.8)
1 dose (4–8 months, any source) 150/264 56.6 (50.1, 62.9)
Dose 1 at ANC (all trimesters) 177/199 88.9 (83.3, 92.8)
Dose 1 by DOT at ANC (all trimesters) 60/173? 33.9 (23.6, 46.0)
2 doses SP{
2 doses (all trimesters, any source) 115/262 43.4 (36.5, 50.5)
2 doses (4–8 months, any source) 103/262 38.9 (32.5, 45.7)
Dose 2 at ANC (all trimesters) 110/115 96.7 (90.0, 98.2)
Dose 2 by DOT at ANC (all trimesters) 28/108? 25.5 (17.2, 36.0)
3 doses SP{
3 or more doses (all trimesters, any source) 21/260 8.1 (4.8, 13.2)
ITN use (amongst sampled women)
ITN used last night 138/149 92.6 (84.7, 96.6)
ITN used during last pregnancy 242/263 92.0 (83.0, 94.8)
ITN sourced from ANC clinic 102/138 73.9 (65.8, 80.7) 196/242 81.0 (75.4, 85.6)
Co-coverage IPTp{ and ITNs
1 dose SP No IPTp1, No ITN 10/262 3.8 (2.0, 7.1)
IPTp1, No ITN 11/262 4.2 (2.2, 7.7)
No IPTp1, ITN 53/262 20.2 (15.1, 26.6)
Both IPTp1 & ITN 188/262 71.5 (65.2,77.0)
2 doses SP No IPTp2, No ITN 14/260 5.3 (3.1, 8.9)
IPTp2, No ITN 7/260 2.7 (1.2, 5.9)
No IPTp2, ITN 131/260 50.4 (43.0, 57.8)
Both IPTp2& ITN 108/260 41.5 (35.2, 48.2)
IPTp1, one dose of SP; IPTp2, two doses of SP; DOT, directly observed therapy; ITN, insecticide treated net; ANC: antenatal clinic; IPTp, intermittent preventive treatment;
N, denominator; n, numerator; CI, confidence interval; IQR, inter-quartile range; SP, sulfadoxine-pyrimethamine.
{Excludes women who did not receive IPTp and who were taking cotrimoxazole as documented on ANC cards.
?missing records.
doi:10.1371/journal.pone.0092102.t002
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Methods
Ethical Considerations
The study was approved by the ethical committees of the
Faculty of Medicine, Pharmacy and Odonto-stomatology of
Bamako, the Liverpool School of Tropical Medicine, and the
London School of Hygiene and Tropical Medicine. Written
informed consent was obtained from women prior to being
interviewed at home and for adolescents who were not considered
mature minors (a person under 18 years of age who is pregnant,
married or a parent), written informed consent was obtained from
the head of the household.
Study Area
The household survey was conducted as part of a larger study to
identify and quantify the major barriers to the scale up and use of
interventions to control malaria in pregnancy at the district,
facility, and community levels in Mali. The study was conducted in
Segou District, Segou Region. Malaria in Segou Region is
seasonal ranging from holo-endemic in the southern part of the
district and meso-endemic to the north. HIV prevalence is 1.3% in
the general population of Segou and 1.7% in women aged 15–49
years [19]. Segou District has a total population of 448,552
projected from the 1998 census, with more than 60% of this
population living in rural areas. The most common ethnic groups
are Bamanan and Sarakole/Soninke, and the main economic
occupation of the occupants is subsistence agriculture.
The health care system in Mali is severely under-resourced. The
government funds health facilities down to district level only,
comprising one hospital and one district level health centre termed
the Centre de Sante´ de Reference (CSRef). All health facilities
below this level, at what is termed the operational level, are funded
by communities themselves through a concept developed initially
as the ‘Bamako Initiative’ [20]. This engagement was done to push
external partners and the government to transfer responsibility to
the community for the creation, organisation and management of
community health services (CSCom) through the ASACO
(community health association) created in each ‘health area’. At
the time of the study, Segou District had a total of 26 functioning
health structures, 18 of which were owned by the community (i.e.
headed by a nurse paid by the community) and 8 of which were
headed by a physician paid by the government. The government
facilities comprised 1 hospital and 1 district level health facility
(CSRef) based in Segou town (district headquarters).
Malaria in pregnancy services provided through Consultation
Pre´natale (CPN, or ANC) include 2 doses of IPTp administered by
directly observed therapy (DOT) between month 4 and 8
(inclusive) gestation, with each dose given at least one month
apart, and 3 doses for women who are HIV positive, and provision
of a free long-lasting insecticide treated net (LLIN) to all women at
first ANC visit in areas of high transmission [21].
National level Demographic and Health Survey (DHS) data
available at the time the study was designed (DHS 2006) showed
that 63% of women made two or more ANC visits, 4% pregnant
women received two doses of IPTp-SP during ANC visits and 39%
of pregnant women used an ITN the night before the survey [19].
The IPTp and ITN coverage figures for Segou Region were
similar to the national average, with 3.8% of pregnant women
reporting having received two doses of IPTp and 43% reporting
having used an ITN the night before the survey.
Study Design and Selection of Study Participants
A two stage cluster sampling household survey was undertaken
over a period of 3 weeks in September 2009 during the rainy
season. Enumeration areas from the 1998 census were used to
select 40 villages, representing clusters, with probability propor-
tional to size. The primary endpoint for sample size calculation
was the proportion receiving 2-doses of IPTp. A sample size of 213
women of child-bearing age (15–49 years) was sufficient to
estimate an uptake of 50%, with a precision of 6%, a design
effect of 1.75 and 10% non-response. To obtain an evaluable
sample of 213 women, the initial sample size was set at 624 [22]
based on the hypothetical assumptions that 53% of women
attending ANC are offered the first dose of IPTp, of which 99%
take it, of which 65% return for a second ANC visit, of which
100% receive the second dose of IPTp
(62460.5360.9960.65 = 213).
A total of 16 households were randomly selected within each
cluster using a modified EPI sampling technique. By using this
method the sample was self weighted. One respondent within each
household was selected using a set of predefined criteria as follows:
women must be aged 15–49 years; pregnant women were
Figure 1. Timing of first ANC visit among recently pregnant women who attended ANC (N=215). ANC, antenatal clinic.
doi:10.1371/journal.pone.0092102.g001
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prioritised over mothers of children aged under one year, who
were prioritised over other non-pregnant women; and if more than
one woman was currently pregnant/mother of a child aged under
one year/aged 15–49 years, the woman most closely related to the
head of the household was interviewed (i.e. wife. daughter.
sister. niece/aunt. daughter-in-law).
Data Collection Instrument
The questionnaire sought to obtain key coverage indicators on
the frequency and timing of ANC attendance, the frequency,
timing and source of IPTp-SP doses with or without DOT, ITN
use during the current/most recent pregnancy and source.
Additional questions explored women’s knowledge of malaria in
pregnancy in relation to use of IPTp and ITNs, and whether HIV
status alters behaviour patterns and uptake. A composite malaria
knowledge score was created based on the cumulative score of
correct responses in relation to source of malaria (mosquitoes),
consequences of malaria in pregnancy to mother (anaemia) and
unborn child (miscarriage, low birth weight (LBW), premature
birth, still birth) and of methods to prevent malaria in pregnancy
Figure 2. Number of IPTp doses received by trimester at 1st ANC visit among recently pregnant women. IPTp, intermittent preventive
treatment; ANC, antenatal clinic.
doi:10.1371/journal.pone.0092102.g002
Figure 3. Cumulative effectiveness{ of ANC to deliver IPTp and ITNs among recently pregnant women. IPTp, intermittent preventive
treatment; IPTp1, first dose; IPTp2, second dose; ANC, antenatal clinic; DOT, directly observed therapy; ITN, insecticide treated net. {Cumulative
systems effectiveness represents successful coverage of women for each of the intermediate steps up to that point in the delivery system.
doi:10.1371/journal.pone.0092102.g003
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(e.g. ITNs, nets and/or ITNs). HIV status was self-reported, and
additional indirect questions about recognition and use of
cotrimoxazole and history of episodes of opportunistic infections
associated with HIV were included. Self-reported IPTp, ITN and
ANC practices, including HIV testing and results, were compared
with data contained in ANC cards where available. Recording of
household assets to develop a wealth index and observation of
household ITNs in situ was also performed. Principle components
analysis was used to construct a wealth index in order to assess the
effect of socio-economic status (SES) [23,24]. Household charac-
teristics such as education of the household head, floor material,
source of drinking water, type of toilet facility, household
ownership, cooking fuel type, and ownership of a television and
watch were used in the Principle components analysis.
The questionnaire was translated and back translated to ensure
accuracy of translation of concepts and variables, and then pre-
tested. Interviewers were trained to conduct the interviews in the
national spoken language of Bambara, translated directly from the
French translation of the questionnaire.
Data Processing and Analysis
Data from the household surveys were collected on personal
digital assistants. All analyses were adjusted for the survey design
and clustering of households using STATA 11.
This analysis was restricted to pregnant women and mothers of
children under one year, termed ‘recently pregnant women’, given
likely use and potential recall of IPTp and ITNs. Socio-
demographic characteristics of currently and recently pregnant
women were described and compared. Proportions of women
accessing ANC, receipt and timing of each dose of IPTp-SP from
any source and receiving ITNs from any source were quantified.
The indicator for ITN use in currently pregnant women was the
proportion of pregnant women who reported having used an ITN
the night before the survey [25,26], and for recently pregnant
women, the proportion of women who reported having used an
ITN regularly during their most recent pregnancy [27,28].
We used a framework developed previously for effectiveness
analysis, adapted specifically for the delivery of IPTp-SP and ITNs
through ANC to measure delivery system effectiveness using
household data to identify critical points in the delivery system
which were ineffective [9]. The systems effectiveness analysis was
undertaken using women who had been recently pregnant. We
excluded HIV positive women with documented use of cotrimox-
azole, since IPTp with SP is not recommended for women taking
cotrimoxazole due to potential severe adverse events caused by
concomitant use of two sulphur-containing drugs [1]. Systems
effectiveness was defined as the proportion of women attending
ANC who reported having received a full course of IPTp-SP (two
doses of SP) and having used an ITN regularly during the most
recent pregnancy. Two categories of effectiveness analyses were
applied - ‘intermediate process effectiveness’ and ‘cumulative
systems effectiveness’ [29]. Intermediate process effectiveness
represents coverage of women at each of the intermediate steps
in the delivery of IPTp-SP, with the addition of ‘used an ITN’ and
then ‘used an ITN from ANC’ together with taking the second
dose of IPTp as the final process. Intermediate process effective-
ness was calculated as the number of women who successfully
completed the intermediate process (the numerator) as a propor-
tion of all women who reached that point in the delivery system
(the denominator). An intermediate process was described as
ineffective if #80% women successfully completed that step.
Cumulative systems effectiveness represents successful coverage of
women for each of the intermediate steps up to that point in the
delivery system. The final step represents the percent of eligible
women in the community that received both interventions and is
equivalent to a cumulative coverage indicator for several
indicators (two ANC visits, two doses of SP (IPTp) and ITN use)
that are measured by DHS.
Table 3. Intermediate process and cumulative effectiveness6 of receiving two doses of SP and using an ITN with and without
DOT in an eligible gestational age (4–8 months) among recently pregnant women not taking co-trimoxazole.
2 doses of SP 2 doses of SP by DOT
Intermediate process N n
Intermediate
process
effectiveness
± % (95% CI)
Cumulative delivery
effectiveness? % N n
Intermediate
process
effectiveness
± % (95% CI)
Cumulative delivery
effectiveness? %
Attend ANC at least once 213 125 58.7 (50.3, 66.6) 58.7 213 125 58.7 (50.3, 66.6) 58.7
Took IPTp1 125 102 81.6 (72.1, 88.4) 47.9 125 102 81.6 (72.1, 88.4) 47.9
Took IPTp1 by DOT 91{ 30 33.0 (19.7, 49.7) 15.8
Attend ANC at least twice 102 93 91.2 (82.2, 95.8) 43.7 30 29 96.7 (77.4, 99.6) 15.3
Took IPTp2 92 61 66.3 (57.4, 74.2) 29.0 29 15 51.7 (34.3, 68.7) 7.9
Took IPTp2 by DOT 15 12 80.0 (49.9, 95.1) 6.3
Took IPTp2 & used an ITN
during last pregnancy
61 55 90.2 (78.2, 95.9) 26.2
Took IPTp2 & used an ANC ITN
during last pregnancy
55 51 92.7 (81.6, 97.3) 24.3
Took IPTp2 by DOT & used an
ANC
ITN during last pregnancy
12 11 91.7 (46.8, 99.3) 5.8
IPTp1: one dose of SP; IPTp2: two doses of SP; DOT: directly observed therapy; ITN: insecticide treated net; ANC: antenatal clinic; IPTp, intermittent preventive treatment;
SP, sulfadoxine-pyrimethamine; N, denominator; n, numerator; CI confidence interval.
{11 missing records.
6Intermediate process effectiveness represents coverage of women at each of the intermediate steps in the delivery of IPTp;
?Cumulative systems effectiveness represents successful coverage of women for each of the intermediate steps up to that point in the delivery system.
doi:10.1371/journal.pone.0092102.t003
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The effectiveness analyses for IPTp were performed on women
first attending ANC in an eligible month of gestation (4 to 8
months) for IPTp and excluded women who were taking
cotrimoxazole as documented on ANC cards. We did not take
into account the dosing interval. These analyses were conducted
under two scenarios, Scenario A where the criteria of receiving
IPTp-SP by DOT was not included, and Scenario B where
receiving IPTp-SP by DOT was included. The systems effective-
ness analysis for ITNs was not restricted by gestational age as
policy states ITNs are to be delivered to women at their first ANC
visit regardless of gestational age.
Univariate analyses of potential predictors of receipt of: i) at
least one ANC visit between 4–8 months gestation ii) two doses of
IPTp-SP (with or without DOT); iii) one dose of SP by DOT; and
iv) two doses of SP by DOT (as the four least effective processes
identified), were conducted. Logistic regression models for survey
design were used, and adjusted Wald tests were applied to test for
associations between predictors and outcomes. Predictors of ITN
use explored included selected individual and household socio-
demographic factors (women’s age, marital status, education,
malaria knowledge using the composite malaria knowledge score,
residence, and SES); person: net ratio stratified according to any
net, ITNs, and LLIN; gravidity; losing a live born child; number
and timing of ANC visits; whether they recently had a malaria
episode and whether they took medicine for that episode. Potential
predictors significant at the 10% level (p#0.1) in the univariate
analyses were included in multivariable logistic models to
determine which factors were associated with the outcomes after
accounting for other potential predictors. Interactions between
paired predictors were assessed for all predictors included in the
models.
We estimated the potential and actual effectiveness of the IPTp
strategy on LBW extrapolated to the pregnant population of
Segou Region (n = 116,813). We used the protective efficacy of
IPTp on LBW of 35% among women protected by 2-doses of
IPTp-SP and an ITN in any pregnancy observed in a cross
sectional study from 2007 to 2009 in 5 districts of Mali (adjusted
prevalence ratio (APR) 0.57; 95% CI 0.40, 0.80) and an incidence
of LBW of 12% in women not receiving IPTp (Kassoum
Kayentao, personal communication), and co-coverage with IPTp
by DOT and ITNs, using the following formula [30]:
Number of LBW babies averted
~Target population x Incidence LBW
xProtective efficacy xCoverage
Results
Study Population
A total of 637 women of childbearing age were interviewed
(99.5% response rate) of which 150 were pregnant (24%) and 264
(41%) were recently pregnant women. Among the pregnant
women, the majority were in their second or third trimester (87%,
132/150) and the mean gestational age was 6 months (IQR 4–8)
(Table 1). The majority of women were multigravidae, with a
median number of births in the pregnant and recently pregnant
groups of 3 (IQR 2–6) and 4 (IQR 2–6) respectively. The median
age was 27 years (IQR 22–30) among pregnant women and 25
years (IQR 21–30) among recently pregnant women. The majority
of women in both groups were married (.90%), and lived in rural
areas (.67%). The main ethnic group was Bambara (.55%) and
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about two-thirds of women had no education (.62%). Almost half
(45%; 60/134, 16 missing values) of pregnant women and over a
third of recently pregnant women (37%; 99/265) had lost a live
born child. Self reported HIV prevalence was very low, 0% among
pregnant women and 2% (1/50) among recently pregnant women.
Coverage Indicators
Access to ANC and timing of first ANC visit. Among
recently pregnant women, 81% (215/264) of women reported
attending ANC at least once, 75% (198/264) at least twice and
42% (112/264) made four or more visits, with a median number of
4 ANC visits (IQR 3–5) (Table 2). Just over 40% of women first
attended ANC in their first trimester, with almost half initiating
attendance in their second trimester (47%) (Figure 1). Attendance
among pregnant women was lower (63% for one visit and 43% for
two visits), with a median of 2 visits (IQR 1–3), as would be
anticipated given that 54% of women were still in their first or
second trimester (Table 2). The median month of gestation at first
ANC visit was 4 months in both groups of women (IQR 3–5).
Number of IPTp doses and timing of receipt. Three-
quarters of recently pregnant women (not taking cotrimoxazole)
reported receiving one dose of SP in any trimester from any source
(75%; 199/264), and 57% (150/264) in women who received
doses in an eligible month (Table 2). The majority of women
reported receiving the first dose of SP at ANC (89%; 177/199) but
only 34% said they received it under DOT (60/173, 4 missing
values). Only 43% (115/262) of recently pregnant women
reported receiving the recommended second dose of SP (any
trimester, any source), and only 39% (103/262) in an eligible
trimester. The majority (97%) of women reported receiving the
second dose of SP from ANC of which only a quarter (26%)
reported receiving it by DOT. A small proportion of women (8%)
reported receiving three doses of SP in any trimester from any
source.
IPTp coverage by number and timing of ANC
visits. Among recently pregnant women the mean number of
doses of SP showed an increasing trend with increasing number of
ANC visits. Similarly, the number of doses of SP received was
associated with gestational age at first ANC visit, with fewer
recently pregnant women receiving a second dose of SP if they first
attended ANC in their second or third trimesters (p = 0.01)
(Figure 2).
ITN use and co-coverage with ITNs and IPTp. Among
pregnant women, 93% (138/149) reported using an ITN the
previous night and similarly 92% (242/263) of recently pregnant
women reported using an ITN regularly during their most recent
pregnancy. Approximately three-quarters of women in both
groups reported obtaining the net used in pregnancy from ANC
(74% and 81% of pregnant and recently pregnant women
respectively). In terms of co-coverage of ITN use and IPTp
receipt among recently pregnant women, 72% (188/262) reported
using an ITN and receiving one dose of SP and 42% (108/260) of
using an ITN and receiving two doses of SP. Whilst few women
reported using neither ITN nor one or two doses of SP (4% and
5% respectively), a large proportion of women reported using an
ITN alone in the absence of any SP, with 20% (53/262) and 50%
(131/260) of ITN users who reported not having received one and
two doses of SP respectively.
System Effectiveness of IPTp and ITN Delivery through
ANC
IPTp with or without DOT. Although 81% of recently
pregnant women visited ANC at least once (Table 1), only 59%
(125/213) of women not taking co-trimoxazole made their first
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ANC visit in an eligible gestational age for receiving IPTp
(Figure 3). Of these, 82% (102/125) received the first dose of SP,
and of the 91% (93/102) of women who returned for a second
ANC visit, only 66% (61/92) received a second dose (Table 3).
Only 24% (55/213) of women received the recommended two
doses of SP and used an ITN during pregnancy. There were two
intermediate processes in the delivery system that were #80%
effective – women first attending ANC in an eligible gestational
age for IPTp, and the receipt of the second dose of SP. ITN use
among women receiving two doses of SP was .90%.
IPTp given by DOT. With respect to DOT, the cumulative
system effectiveness was substantially lower, with only 6% of women
receiving two doses of SP by DOT and using an ITN (Table 3)
(Figure 3). The intermediate processes that were #80% effective
were, in addition to first attending ANC in an eligible gestational age
for IPTp, receipt of the first dose of SP under DOT (33%), receipt of
a second dose of SP (52%) and receipt by DOT (80%). ITN use
among women receiving two doses of SP by DOT was 92%.
ITNs. Among the 81% of recently pregnant women who
attended ANC at least once, 93% (200/215) reported using an
ITN during their last pregnancy of which 85% (169/200) were
obtained from ANC (Table 4). Among the 63% (94/150) of
pregnant women who attended ANC at least once, 95% (88/93)
reported using an ITN the previous night, of which 86% (76/88)
were sourced from ANC.
Predictors of IPTp Receipt
Two doses of SP. The univariate predictors of recently
pregnant women reporting having received two doses of SP were:
number of ANC visits and timing of 1st ANC visit (Table 5). The
odds of women reporting receipt of two doses of SP progressively
decreased the later the woman made her first ANC visit (OR 0.24,
95% CI 0.09, 0.67 for 7–9 months vs. 1–3 months gestation) and
increased with number of ANC visits (OR 12.00, 95% CI 1.71,
47.91 for 3 vs. 1 visit). After adjustment, no factors were
independently associated with receipt of two doses of SP among
recently pregnant women (Table 5).
One and two doses of SP by DOT. The univariate
predictors of recently pregnant women reporting that they
received one dose of SP by DOT were SES and marital status,
and for two doses of SP by DOT, marital status and distance to the
local health facility (Table 6). After adjustment, being unmarried
was an independent predictor for receiving either dose of SP by
DOT (AOR 0.10, 95% CI 0.03, 0.40 for married women
receiving 2 doses by DOT), and women who lived .5 km from
the local health facility were also more likely to report receipt of
two doses of SP by DOT (AOR 0.34, 95% CI 0.14, 0.83 for
women living ,5 km from a health facility).
Predictors of ITN Use
The univariate predictors of recently pregnant women reporting
using an ITN in pregnancy were being married (OR 3.5, 95% CI
1.00, 12.60), age, distance form health facility and person: LLIN
ratio. Adolescents were less likely to use ITNs than older women
(OR 0.30, 95% CI 0.13, 0.74) as were women who lived ,5 km
from a health facility (OR 0.32, 95% CI 0.10, 1.04) and who lived
in a household with a high person: LLIN ratio (OR 0.26 95% CI
0.06, 1.12 for 4+ vs. ,2 persons per net) (Table 7). After
Table 7. Univariate and multivariate analysis of predictors of using an ITN among recently pregnant women.
Recently pregnant women (N=263)
Determinant n % OR 95% CI P value AOR 95% CI P value
Parity 0.06 0.4
Para 1 9 77.8 1 1
Para 2–4 123 89.4 2.45 0.98,6.14 1.70 0.48,6.01
Para 5. 131 95.4
Married 0.05 0.7
No 19 79.0 1 1
Yes 243 93.0 3.5 1.00,12.60 1.46 0.26,8.06
Adolescent 0.01 0.2
No 216 94.0 1 1
Yes 46 82.6 0.30 0.13,0.74 0.43 0.10,1.84
Person: LLIN ratio 0.02 0.004
,2 44 95.5 1 1
2–,4 101 96.0 1.15 0.21,6.25 0.82 0.18,3.65
4+ 58 84.5 0.26 0.06,1.12 0.16 0.04,0.55
Took medicine for
malaria
0.09
No 15 80.0 1 NA
Yes 133 92.5 3.08 0.82,11.56
Distance to facility 0.06 0.09
$5 km 86 96.5 1 1
,5 km 176 89.8 0.32 0.10,1.04 0.23 0.04,1.29
N, denominator; n, numerator, OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; LLIN, long lasting insecticide treated net; km, kilometres; NA, Not
available due to non convergence.
doi:10.1371/journal.pone.0092102.t007
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adjustment the only independent predictor for using an ITN
among recently pregnant women was person: LLIN ratio (AOR
0.16 95% CI 0.04, 0.55 for 4+ household members per LLIN.
Modelled Number of LBW Averted
The potential effectiveness of the malaria in pregnancy
prevention strategy in averting LBW among the pregnant
population of Segou Region was calculated using the effectiveness
data from recently pregnant women not taking cotrimoxazole.
This showed that 59% (126/214) made their first visit in an eligible
trimester and 90% returned to ANC for a second visit (93/103)
(Table 3) and could thus be potential recipients of two doses of SP
by DOT and use of an ITN; and result in a potential 2,914 cases
of LBW averted. However, based on the reported co-coverage of
two doses of SP by DOT and ITNs (5%; 11/214), actual
effectiveness was only 252 cases of LBW averted. The difference
between potential and actual effectiveness is 2,662 cases of LBW
(95% CI 152–4,335) that may have been averted if all women in
Segou Region who attended ANC at least twice had received
IPTp by DOT and used an ITN, equivalent to 228 (95% CI 13–
371) cases of LBW per 10,000 women.
Discussion
We have used household data to assess the ANC attendance
patterns among pregnant women and the relative effectiveness of
the health system in delivering IPTp and ITNs to women through
ANC in Segou District in Mali. Whilst a high percentage of
women made at least two ANC visits (75%), with a significant
proportion of women initiating ANC attendance in their first or
second trimester (88%), only a quarter of women received two
doses of SP and used an ITN, and only 5% received both doses of
SP by DOT and used an ITN. Both ANC attendance patterns
among women and factors affecting the delivery of care at ANC
contribute to the low effectiveness reported.
Women in this setting start their ANC visits earlier than
reported in East Africa [31], and return for multiple visits,
suggesting a favourable pattern of behaviour for the delivery of
ANC services. ANC attendance in the study was slightly higher
than reported in the most recent Mali DHS [19], with 75%
compared to 63% of women making two or more ANC visits, a
higher median of ANC visits (median of 4 compared to 3), and a
higher proportion of women initiating ANC in their first trimester
(41% compared to 30%, with a median of 4 months gestation).
Therefore a high proportion of women were not eligible for the
first dose of IPTp at their first ANC visit, which should only be
given at the start of the second trimester.
Among the women who first attended ANC between 4–8
months gestation, a high proportion reported receiving one dose of
SP, but only a third of doses were given by DOT. However, the
majority of women who received a second dose of SP reported to
have received it by DOT. The poor adherence to DOT, and the
reasons for this, are described in a parallel study using observations
and in-depth interviewers with health providers in a sample of
health facilities in Segou District [32,33]. Observation data
collected in health facilities found provision of IPTp-SP by DOT
to be very low, 0% and 34.3% (95% CI 10.5, 69.8) at district and
community level health facilities, respectively. The main reason for
poor adherence to giving IPTp by DOT reported by the majority
of health workers interviewed was that they had decided, through
personal experience, reports of pregnant women, training, or
supervision that the side effects of SP were such that it should not
be given to pregnant women on an empty stomach. It is possible
that because the second dose of SP is given in the late second or
third trimester, i.e. at a more advanced stage of pregnancy, that
side effects and especially nausea, would be less prevalent hence
the higher number of women who reported receiving the second
dose by DOT. The incidence of side effects to SP by gestational
age together with the perception of this by health workers requires
further investigation. We undertook a similar study in Kenya
where we found the least effective steps in the delivery of SP was
receiving any SP, but when women did receive SP they were more
likely to receive it by DOT than in Mali [9]. This type of analysis
can therefore by useful for highlighting these programmatic
deficiencies, which vary from country to country and also within
the same country.
Figure 4. Documented and reported receipt of first and second dose of SP for IPTp by trimester among pregnant and recently
pregnant women. IPTp, intermittent preventive treatment; SP, sulphadoxine-pyrimethamine.
doi:10.1371/journal.pone.0092102.g004
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Of concern is the finding that just over 20% of recently
pregnant women reported receiving the first dose of SP in their
first trimester, i.e. in an ineligible gestational age of pregnancy.
This may to some extent reflect poor recall or knowledge among
women, nevertheless ANC card data indicated a similar propor-
tion of women were given IPTp in the first trimester, confirming
that there was some practice of providers giving women the first
dose of SP in their first trimester (Figure 4). Confusion among
health providers over the timing of giving IPTp-SP has been
described elsewhere [34], and in the parallel study in Mali, some
health providers stated that women of less than one month
gestation, rather than 1st trimester, should not be given SP [32].
On the basis of a recent meta-analysis showing that three or more
doses of SP are more effective than two doses [35], WHO recently
updated its policy guidance to recommend the administration of
SP to pregnant women at every scheduled antenatal visit starting
in the second trimester [36]. The new guidance is more closely
aligned with the new Focused Antenatal Care schedule of four
visits in the second and third trimesters [36], and is anticipated to
simplify the strategy and improve uptake of IPTp-SP. The release
of this simplified guidance provides an opportunity for countries to
improve the delivery of IPTp-SP, and to retrain health providers
to avoid administering SP in the first trimester.
As anticipated by the high ANC coverage data in Segou
District, a high proportion of women returned to ANC for a
further visit in an eligible gestational age after receiving the first
dose of SP (.90%). However, only just over half of these women
reported receiving a second dose of SP. The two predominant
reasons given by women for not taking the second dose of SP were
that they were not offered it (42%, 22/52) and that they were not
informed a second dose was necessary (37%; 19/52) (data not
shown). It is also possible that women who initiate ANC late
account for some of this drop in effectiveness, as shown in Figure 2;
indeed timing of the first ANC visit was a predictor of receipt of
two doses of SP in the univariate analysis. The exclusion of
administering SP in the 9th month of pregnancy results in a narrow
window of opportunity to administer SP to women who initiate
ANC late. In the parallel study among health workers, there was
considerable misinterpretation of the guidelines, that the 8th
month was inclusive i.e. that SP could not be given in the 8th or 9th
month, and that the first dose should be denied unless a women
could make two scheduled visits for both doses before the end of
her pregnancy [32].
There were no statistically significant predictors of receiving two
doses of SP in multivariate models, though both number ($2 visits)
and knowledge of malaria were associated with receipt in the
univariate analysis, and late first ANC visit with non-receipt of SP.
Predictors of receiving SP by DOT were marital status and
distance from the health facility. Women who were married were
less likely to receive either the first or second dose of SP by DOT,
as were women who lived ,5 km from their local health facility
less likely to receive two doses of SP by DOT. Some studies have
reported that women need their husband’s consent before taking
drugs [37,38], and it may be that unmarried women are more
likely to take SP by DOT as they do not need to wait for their
husband’s consent. Women who live close to a health facility may
argue that they need to return home either to eat first, since
women not wishing to take SP on an empty stomach was a
problem observed by health providers in the parallel health facility
study in Mali [32], or to ask their husbands consent to take the
drugs. Interestingly, less poor women were less likely to receive SP
by DOT in the health facility study undertaken at the same time of
the household survey [33].
ITN use among pregnant and recently pregnant women in this
setting was high, with over 90% of women who had attended ANC
at least once reporting having used an ITN. The effectiveness
analysis suggests that ANC is an effective channel for delivering
ITNs to pregnant women, with 85% of pregnant and recently
pregnant ITN users reporting having used an ITN from ANC.
This is substantially higher use than reported in the 2006 DHS
survey of 30% in Segou Region, as would be anticipated given
ongoing scale up of the national ITN programme, and coverage
was higher in rural areas compared to urban areas nationally (31%
vs. 22%) [19]. This is consistent with our finding that ITN use was
lower among recently pregnant women living within 5 km of a
health facility, which usually have a central location in a village or
town. Married, multigravid women were more likely to use an
ITN in the univariate analysis, and adolescents less likely to use
ITNs, suggesting that adolescents should be a high risk group for
targeting ITNs in this setting. This is consistent with a recent
systematic review and meta-analysis which showed using data
from 19 countries of sub-Saharan Africa that married, multi-
gravid, older women aged.19 years were the most likely to use an
ITN [34]. The only multivariate predictor in our analysis from
Segou District was household person: LLIN ratio which concurs
with findings from another study using standardized national
surveys across 15 countries, which showed that intra-household
access to ITNs was the strongest and most consistent determinant
of use among children [39].
A limitation of household surveys is potential reporting bias
among interviewees, who may over- or under-report access and
usage of interventions for a number of reasons including poor
recall; this may be a general limitation but one which might be
anticipated with regard to gestational age, which is difficult to
interpret in the first trimester and especially among primigravidae.
We measured concordance between reported and documented
information using ANC cards where available, obtained from both
pregnant and recently pregnant women. We found good
concordance between reported and documented data for timing
of first ANC visit (Kappa score 0.6945) and receipt of two doses of
SP (K 0.682), and fair concordance for mean gestational age for
the first and second dose of SP (K 0.249 and 0.206 respectively)
[40]. There was potential selection bias among recently pregnant
women; by selecting women with a child aged under one year,
women who had had a pregnancy loss (miscarriage or stillbirth)
may have been excluded from the recently pregnant group of
women, and these women may have had different health seeking
behaviours. Also, the diminishing numbers in the evaluative
sample in the effectiveness analyses mean the regression analyses
have less statistical power than anticipated. We use women’s self-
report to interpret health provider practices which may not reflect
true events, hence findings are compared with those of the
observation studies in health facilities in the parallel study in Mali,
which support the main findings from our analysis [32,33].
Conclusions
In conclusion, our analysis has shown that ANC is a more
effective delivery channel for ITNs than for IPTp in this setting.
This translates into a loss of community effectiveness of the IPTp
strategy; with the current levels of coverage only 9% of the
potential effectiveness of this strategy is being achieved, and a
further 228 (95%) cases of LBW per 10,000 live births can be
averted by achieving universal coverage of IPTp and ITNs. Loss in
effectiveness is even greater if women who do not attend ANC
were to be considered in this analysis. The practice among women
of attending ANC early, an important element of focussed
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antenatal care, combined with evidence of health providers
administering IPTp in the first trimester together with poor
adherence to giving IPTp by DOT, points to the need to improve
the quality of IPTp provision.
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